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Abstract
The “TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia” (TOPIC) trial was stopped
preliminary, due to lagging inclusions. This study aimed to evaluate the treatment efficacy and clinical applicability
of imiquimod 5% cream in high-grade cervical intraepithelial neoplasia (CIN). The lagging inclusions were mainly
due to a strong patient preference for either of the two treatment modalities. This prompted us to initiate a new
study on the same subject, with a non-randomized, open-label design: the ‘TOPical Imiquimod treatment of
high-grade Cervical intraepithelial neoplasia (TOPIC)-3’ study.
Original TOPIC-trial: Medical Ethics Committee approval number METC13231; ClinicalTrials.gov Identifier: NCT02329171,
22 December 2014.
TOPIC-3 study: Medical Ethics Committee approval number METC162025; ClinicalTrials.gov Identifier: NCT02917746,
16 September 2016.
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Main text
The TOPical Imiquimod treatment of high-grade
Cervical intraepithelial neoplasia (TOPIC) trial started in
January 2015, with the aim to evaluate the treatment
efficacy and clinical applicability of imiquimod 5% cream
in high-grade cervical intraepithelial neoplasia (CIN). A
study protocol for this study was published in BMC
Cancer in February 2016 [1]. Patients were randomized
into one of two treatment arms: the imiquimod treat-
ment arm, in which subjects were treated with imiqui-
mod during 16 weeks, or the standard treatment arm, in
which large loop excision of the transformation zone
(LLETZ) was performed. An earlier version of the study
included a third treatment arm: an observational arm,
which consisted of ‘watchful waiting’ during 20 weeks,
with the aim to evaluate spontaneous regression of
high-grade CIN and identify prognostic biomarkers for
spontaneous regression. The observational arm was
removed from the study after 9 months to increase the
inclusion rate. The current study stopped preliminary in
May 2016 due to lagging inclusions.
The lagging inclusions may be explained by the very
different nature of the treatment modalities and the
strong preferences of women for either imiquimod or
LLETZ treatment. We experienced that women have a
general preference for LLETZ treatment, as it provides a
fast and effective treatment of high-grade CIN. This was
confirmed by a recent patient preference study per-
formed by the author (manuscript in press). This prefer-
ence study also showed that a preference for imiquimod
treatment is largely restricted to women with a future
pregnancy wish and that a treatment efficacy of at least
72% is desired by these women. Indeed, we experienced
that only a subset of women with a future pregnancy wish
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wanted to participate in the study. All of these women
had a strong preference for imiquimod treatment. The
amount of women willing to participate was too small to
achieve the intended study population of 120 in one study
centre, within the time-frame of the study. For this reason,
the study was preliminary stopped.
Twelve women were included in the total duration of
the study: six women were included in the observational
arm, three in the imiquimod arm and three in the stand-
ard treatment arm. Of the women included in the obser-
vational arm, two showed spontaneous regression to
CIN1 or less. Two women showed persistent CIN2 after
10 and 20 weeks and were subsequently treated by
LLETZ. The other two women quit the study immedi-
ately after randomization and were treated by LLETZ.
Of the three women who were randomized for imiqui-
mod treatment, one quit the study immediately after
randomization and was treated by LLETZ. The other
two women completed imiquimod treatment and both
showed disease regression to CIN1 or less.
As a consequence of the very different nature of the two
treatment modalities and the differences in treatment
preferences among different populations of women, imi-
quimod will most likely not develop as a treatment alter-
native for all women with high-grade CIN, but may be
restricted to women with recurrent lesions or a future
pregnancy wish. These insights prompted us to initiate a
new study comparing the treatment efficacy and clinical
applicability of imiquimod 5% cream to LLETZ treatment
in high-grade CIN, in selected populations of women with
a preference for either of the two treatment modalities.
The ‘TOPical Imiquimod treatment of high-grade Cer-
vical intraepithelial neoplasia (TOPIC)-3 study’ is a multi-
center, open-label, non-randomized, controlled study,
evaluating treatment efficacy, side-effects and quality of
life associated with imiquimod treatment of high-grade
CIN lesions in a selected population of women who prefer
imiquimod treatment instead of LLETZ. The study also
aims to develop a biomarker profile to predict clinical re-
sponse to imiquimod treatment. This enables selection of
patients in which good treatment response is expected.
The study was approved by the Medical Ethics Committee
AZM/UM (approval number METC162025) and has been
registered on ClinicalTrials.gov (ClinicalTrials.gov Identi-
fier: NCT02917746, 16 September 2016). The study
started recruiting patients in November 2016.
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